Intravenous Iron Supplement to Prevent Postoperative Delirium After Hip Fracture Surgery

• Status: Recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a clinical trial to evaluate the effect of intravenous iron supplement with Ferinject (Ferric Carboxymaltose) in preventing postoperative delirium after hip fracture surgery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Bundang Hospital
• Collaborator: JW Pharmaceutical

Criteria

Inclusion Criteria:

• femur neck fracture, intertrochanteric fractures

• Iron deficiency anemia (Hb<12 in women, Hb<13 in men)

• Iron deficiency (Serum ferritin <100ug/L or transferrin saturation<20%)

• Who understands this clinical trial and volunteers and agrees to this trial

Exclusion Criteria:

• Patient under the age of 65 years

• Hb<7 or someone who has acute symptom of anemia(tachycardia, dyspnea, or dizziness)

• High energy trauma

• Preoperative delirium

• MMSE<10

• Underlying disease which involves cognitive dysfunction (e.g. neurovascular diseases, acute myocardial infarction, pulmonary embolism)

• Those who are inappropriate to participate in the clinical trial assessed by the investigators